| Bioactivity | QM385 is a potent sepiapterin reductase (SPR) inhibitor with an IC50 of 1.49 nM, which blocks T-cell proliferation and autoimmunity at nanomolar potency and with good oral bioavailability[1]. | ||||||||||||
| Target | IC50: 1.49 nM (Sepiapterin reductase) | ||||||||||||
| Invitro | QM385 effectively inhibits the proliferation of human CD4+ T cells at low doses[1]. | ||||||||||||
| Name | QM385 | ||||||||||||
| CAS | 2093421-02-2 | ||||||||||||
| Formula | C17H18F3N7O2 | ||||||||||||
| Molar Mass | 409.37 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Cronin SJF, et al. The metabolite BH4 controls T cell proliferation in autoimmunity and cancer. Nature. 2018 Nov;563(7732):564-568. |